Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Stoke Therapeutics, Inc. Director's Dealing 2021

Mar 4, 2021

32172_dirs_2021-03-04_0d2df961-7a31-4c05-898d-1f978e81042a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Stoke Therapeutics, Inc. (STOK)
CIK: 0001623526
Period of Report: 2021-03-02

Reporting Person: Nash Huw M. (COO & CBO)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-03-02 Employee Stock Option (Right to Buy) $60.00 A 65600 Acquired 2031-03-01 Common Stock (65600) Direct

Footnotes

F1: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.